Want to see HK:1312 full AI Analyst Report?
1312 Stock Chart & Stats
HK$0.03
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.03
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.02 - HK$0.05
Previous CloseN/A
Volume162.00K
Average Volume (3M)9.95M
Market Cap
HK$184.10M
Enterprise ValueHK$186.41
Total Cash (Recent Filing)HK$66.06M
Total Debt (Recent Filing)HK$203.68M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding5,588,572,000
10 Day Avg. Volume1,701,000
30 Day Avg. Volume9,954,100
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.18
P/FCF Ratio3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsSustained gross margins near 49%–58% indicate favorable product economics, pricing capability, or mix. This provides a foundation for future profitability if the company can control operating costs and convert gross profit into positive EBIT.
Accelerating Revenue GrowthThe sharp 2025 revenue acceleration suggests expanding commercial activity or a larger contribution from newer products or markets. Continued growth could improve operating leverage over time, although the company must demonstrate that the expansion is repeatable.
Improving Cash Flow And LeveragePositive recent cash generation and lower debt relative to equity reduce immediate balance-sheet pressure and improve financial flexibility. These trends can support operations and investment, provided cash conversion remains durable and becomes better aligned with earnings.
Bears Say
Persistent Operating LossesNegative EBIT and EBITDA show that strong gross margins are not covering operating expenses, charges, or other costs. The sharply wider 2025 net loss indicates weak operating leverage and leaves profitability dependent on a substantial cost or business-model improvement.
Equity Erosion And Weak ReturnsA shrinking equity base combined with deeply negative ROE signals that losses are eroding shareholder capital rather than generating sustainable returns. If this persists, it could reduce financial resilience and constrain the company’s ability to fund growth internally.
Inconsistent Cash-flow QualityRecent positive cash flow is encouraging, but the longer record is uneven and its relationship with reported earnings is unclear. Earlier negative free cash flow and weak 2025 cash-flow quality make it difficult to treat current cash generation as a dependable long-term strength.
Kontafarma China Holdings Ltd News
1312 FAQ
What was Kontafarma China Holdings Ltd’s price range in the past 12 months?
Kontafarma China Holdings Ltd lowest stock price was HK$0.02 and its highest was HK$0.05 in the past 12 months.
What is Kontafarma China Holdings Ltd’s market cap?
Kontafarma China Holdings Ltd’s market cap is HK$184.10M.
When is Kontafarma China Holdings Ltd’s upcoming earnings report date?
Kontafarma China Holdings Ltd’s upcoming earnings report date is Apr 01, 2027 which is in 211 days.
How were Kontafarma China Holdings Ltd’s earnings last quarter?
Kontafarma China Holdings Ltd released its earnings results on Aug 28, 2026. The company reported -HK$0.012 earnings per share for the quarter.
Is Kontafarma China Holdings Ltd overvalued?
According to Wall Street analysts Kontafarma China Holdings Ltd’s price is currently Overvalued.
Does Kontafarma China Holdings Ltd pay dividends?
Kontafarma China Holdings Ltd pays a Annually dividend of HK$0.004 which represents an annual dividend yield of N/A. See more information on Kontafarma China Holdings Ltd dividends here
What is Kontafarma China Holdings Ltd’s EPS estimate?
Kontafarma China Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kontafarma China Holdings Ltd have?
Kontafarma China Holdings Ltd has 5,588,572,000 shares outstanding.
What happened to Kontafarma China Holdings Ltd’s price movement after its last earnings report?
Kontafarma China Holdings Ltd reported an EPS of -HK$0.012 in its last earnings report. Following the earnings report the stock price went up 3.125%.
Which hedge fund is a major shareholder of Kontafarma China Holdings Ltd?
Currently, no hedge funds are holding shares in HK:1312
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kontafarma China Holdings Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kontafarma China Holdings Ltd
Kontafarma China Holdings Ltd. directs its business efforts through two principal segments: Pharmaceutical and Fitness. Its Pharmaceutical arm is responsible for the manufacturing and marketing of prescription medications and associated laboratory goods. Meanwhile, the Fitness division oversees the management of health clubs, delivers advisory services for physical well-being and health-related pursuits, and runs a franchise model to generate royalty revenue. Established on March 21, 2011, the company maintains its corporate headquarters in Hong Kong.
Technical Analysis
China National Building Material Co
―
Xinyi Glass Holdings
―
China Glass Holdings Limited
―
China Tianrui Group Cement Co., Ltd.
―
YCIH Green High-Performance Concrete Co., Ltd. Class H
―